| Beacon Lighting Group Limited (BLX) ORDINARY FULLY PAID |
Consumer Discretionary |
$373 |
BLX - Appendix 4E June 2025
|
28 Aug 2025 8:31AM |
$3.600 |
$1.625 |
fallen by
54.86%
|
|
BLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 1.6% to $328,918,000.
- Profit after tax decreased by 2.4% to $29,368,000.
- Final dividend declared at 3.9 cents.
- Net tangible asset per share is $0.7378.
- Dividend reinvestment plan reintroduced in FY2023.
- Financial statements audited with no disputes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$166 |
FY25 Investor Results Presentation
|
28 Aug 2025 8:30AM |
$0.895 |
$1.398 |
risen by
56.15%
|
|
SDI - Price-sensitive ASX Announcement
Full Release
Key Points
- EBITDA $21.3 million
- Revenue of $110.4 million, slight decline from previous year
- Gross Profit Margin increased to 62.9%
- Europe and Brazil showed strong sales growth
- North American sales declined due to Amalgam
- Stela product reached $2.5 million in sales
- Project Montrose underway, completion expected in December 2027
- Continued investment in production automation and R&D
- Focus on Aesthetics and Whitening product categories
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$166 |
FY25 Investor Results Presentation
|
28 Aug 2025 8:30AM |
$0.895 |
$1.398 |
risen by
56.15%
|
|
SDI - Price-sensitive ASX Announcement
Full Release
Key Points
- SDI Limited reported a revenue of $110.4 million for FY25, marking a slight decline of 0.7% from the previous period.
- The European and Brazilian markets showed significant growth, while direct exports and markets in the Middle East and Africa faced declines.
- The gross profit margin improved to 62.9%, an increase of 80 basis points, driven by operational efficiencies and a favorable product and geographical mix.
- EBITDA was reported at $21.3 million, showing a minor decrease from FY24.
- Net profit after tax increased to $12.2 million, with normalised NPAT slightly rising to $10.5 million.
- SDI continues to invest in operational efficiency through new equipment and automation, including projects like the Composite Syringe Machine and Nozzle & Tip Packing Machine.
- The company is also focused on expanding its ESG initiatives, planning to publish an inaugural ESG report and enhance reporting according to AASB S2 standards.
- Project Montrose is underway, with construction tenders received, and the project is expected to be funded by a sale and leaseback of current premises and debt.
- SDI plans to release 1 to 2 new products in the upcoming 12 months, focusing on Aesthetics and Whitening categories.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$166 |
Media Release June 25 Results
|
28 Aug 2025 8:30AM |
$0.895 |
$1.398 |
risen by
56.15%
|
|
SDI - Price-sensitive ASX Announcement
Full Release
Key Points
- Total sales for FY 2025 were $110.4 million, down 0.7% on previous corresponding period.
- Gross margin increased to 62.9% due to operational efficiencies and product mix.
- Operating expenses rose by 3.5% to $53.9 million.
- EBITDA decreased by 2.7% to $21.3 million.
- Reported EPS grew by 16.6% to 10.23 cents.
- Normalised EPS showed a slight increase of 0.1% to 8.83 cents.
- Aesthetic product sales showed growth of 4.0%, while Amalgam sales saw a decline of 21.9%.
- European and Brazilian markets showed good growth, whereas Middle Eastern and Asian markets declined.
- New production machinery is expected to further improve gross margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Great Southern Mining Limited (GSN) ORDINARY FULLY PAID |
Materials |
$24 |
Funds received from asset sale - Duketon exploration update
|
28 Aug 2025 8:30AM |
$0.025 |
$0.021 |
fallen by
16%
|
|
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$166 |
Dividend/Distribution - SDI
|
28 Aug 2025 8:30AM |
$0.895 |
$1.398 |
risen by
56.15%
|
|
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$166 |
Preliminary Final Report
|
28 Aug 2025 8:30AM |
$0.895 |
$1.398 |
risen by
56.15%
|
|
SDI - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax increased by 16.7% to $12.2 million.
- Sales decreased by 0.7% to $110.4 million.
- Gross profit margin improved to 62.9%.
- Earnings per share rose by 16.6% to 10.23 cents.
- Final dividend maintained at 1.90 cents per share.
- Growth in European and Brazilian markets.
- Decline in Amalgam sales due to product nearing end of life.
- Focus on operational efficiencies and product margin improvement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$166 |
Preliminary Final Report
|
28 Aug 2025 8:30AM |
$0.895 |
$1.398 |
risen by
56.15%
|
|
SDI - Price-sensitive ASX Announcement
Full Release
Key Points
- SDI Limited reported a net profit after tax increase of 16.7% to $12.2 million for the year ended 30 June 2025.
- Sales for the fiscal year were $110.4 million, a decrease of 0.7% from the previous year.
- There was a noted improvement in the product margin to 62.9%, up by 80 basis points due to operational efficiencies and geographical and product mix.
- Operating expenses increased by 3.5% to $53.9 million.
- EBITDA decreased by 2.7% to $21.3 million.
- Earnings per share increased by 16.6% to 10.23 cents.
- A final ordinary dividend of 1.90 cents was declared, unchanged from the previous year.
- Good growth was observed in the European and Brazilian markets, offset by declines in the Middle Eastern and Asian markets.
- The company noted a continued decline in Amalgam product sales.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Appen Limited (APX) ORDINARY FULLY PAID |
Information Technology |
$248 |
Investor Presentation
|
28 Aug 2025 8:30AM |
$0.890 |
$0.925 |
risen by
3.93%
|
|
| Appen Limited (APX) ORDINARY FULLY PAID |
Information Technology |
$248 |
H1 FY25 results and FY25 outlook & guidance
|
28 Aug 2025 8:29AM |
$0.890 |
$0.925 |
risen by
3.93%
|
|
APX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased 2% to $102.1 million in H1 FY25.
- Strong financial performance in China, with a 67% revenue increase.
- US AI market volatility impacted the overall performance.
- FY25 revenue expected at low end of $235 - $260 million range.
- Positive full year underlying EBITDA expected.
- Identified $10 million in cost efficiencies.
- Continued execution of technology innovation strategy.
- Limited visibility for resumption of large LLM projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Appen Limited (APX) ORDINARY FULLY PAID |
Information Technology |
$248 |
H1 FY25 results and FY25 outlook & guidance
|
28 Aug 2025 8:29AM |
$0.890 |
$0.925 |
risen by
3.93%
|
|
APX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $102.1 million, a 2% increase from the previous period.
- China business revenue grew by 67% to $42.2 million.
- Underlying EBITDA improved with a $2.2 million loss.
- Strategic focus on technological innovation and cost efficiencies.
- Projected $10 million in annual cost savings by FY25 end.
- US Government division investment reduction due to policy uncertainties.
- FY25 revenue guidance towards the lower end of $235-$260 million range.
- Positive full-year underlying EBITDA expected.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Count Limited (CUP) ORDINARY FULLY PAID |
Industrials |
$223 |
Count announces strong Revenue and Profit Growth for FY25
|
28 Aug 2025 8:29AM |
$0.990 |
$1.050 |
risen by
6.06%
|
|
CUP - Price-sensitive ASX Announcement
Full Release
Key Points
- Count Limited announced strong revenue and profit growth for FY2025.
- Cost synergies from the integration of Diverger exceeded expectations.
- Revenue rose by 28% to $143.6 million.
- Underlying EBITA increased by 67% to $27.7 million.
- Statutory EBITA increased by 144%.
- Underlying NPAT reached $10.9 million, an 89% improvement from FY2024.
- Funds Under Advice grew by 10%, and Funds Under Management increased by 24%.
- Successful execution of M&A strategy and divestment of under-performing assets.
- Final dividend declared at 2.75 cents per share, a 22.2% increase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Count Limited (CUP) ORDINARY FULLY PAID |
Industrials |
$223 |
Count announces strong Revenue and Profit Growth for FY25
|
28 Aug 2025 8:29AM |
$0.990 |
$1.050 |
risen by
6.06%
|
|
CUP - Price-sensitive ASX Announcement
Full Release
Key Points
- Count Limited announced strong financial performance for FY2025.
- Revenue increased by 28% to $143.6 million.
- Underlying EBITA grew by 67% to $27.7 million.
- Statutory EBITA rose by 144% to $24.9 million.
- Underlying NPAT improved by 89% to $10.9 million.
- Funds Under Advice increased by 10% to $37.8 billion.
- Funds Under Management rose by 24% to $3.9 billion.
- Completion of eleven transactions as part of their M&A strategy.
- Declared a final dividend of 2.75 cents per share, a 22.2% increase.
- Significant cost synergies from Diverger integration, exceeding expectations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Appen Limited (APX) ORDINARY FULLY PAID |
Information Technology |
$248 |
Appendix 4D and Interim Financial Report
|
28 Aug 2025 8:29AM |
$0.890 |
$0.925 |
risen by
3.93%
|
|
APX - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory net loss after tax of $19.3 million for the half-year ended 30 June 2025.
- One-off amortisation and restructuring costs impacted financial results.
- Focus on improving data quality, operational efficiency, and technology innovation.
- No interim dividend will be paid for the period.
- Cash balance increased to $60.9 million.
- Decrease in trade receivables and current liabilities due to timing of collections and payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Appen Limited (APX) ORDINARY FULLY PAID |
Information Technology |
$248 |
Appendix 4D and Interim Financial Report
|
28 Aug 2025 8:29AM |
$0.890 |
$0.925 |
risen by
3.93%
|
|
APX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased to $102.1 million for the half-year ended 30 June 2025.
- Net loss after tax was $19.3 million.
- Global Services and New Markets are the two main revenue segments.
- New Markets segment faced significant challenges.
- Cash and cash equivalents at $60.9 million.
- Report prepared in compliance with Australian Accounting Standards.
- Includes financial statements, equity details, and auditors' review.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$9 |
Financial Year 2025 Results Announcement & Summary
|
28 Aug 2025 8:29AM |
$0.150 |
$0.018 |
fallen by
88%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for FY25 totalled $12.1 million, an 86% increase from FY24.
- Gross profit for FY25 was $5.4 million, an 80% increase from FY24.
- Loss after income tax for FY25 was $16.8 million, a reduction from $23.1 million in FY24.
- Total expenses decreased by 11% to $25 million in FY25.
- The company raised $11.5 million in capital to fund its operations.
- The full annual report for FY25 will be released in late September.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$9 |
Financial Year 2025 Results Announcement & Summary
|
28 Aug 2025 8:29AM |
$0.150 |
$0.018 |
fallen by
88%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for FY25 increased by 86% to $12.1 million.
- Gross profit rose by 80% to $5.4 million with a margin of 45%.
- Other income increased by 36% due to R&D tax incentives.
- Total expenses decreased by 11% to $25.0 million.
- Net loss after income tax reduced by $6.3 million to $16.8 million.
- A $11.5 million capital raise in Q1 FY25 provided financial support.
- No short-term incentives awarded to executives due to product validation delays.
- The company remains focused on sustainable revenue growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Star Minerals Limited (SMS) ORDINARY FULLY PAID |
Materials |
$10 |
Drilling Highlights Shallow Gold in Western Extension
|
28 Aug 2025 8:29AM |
$0.064 |
$0.039 |
fallen by
39.06%
|
|
SMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Star Minerals Limited focuses on Tumblegum South Gold Project.
- Production expected to start early 2026.
- Agreement with MEGA Resources for mine development.
- Gold prices projected between A$3,000 and A$3,800 per ounce.
- Updated production target: 167kt at 2.43g/t to 255kt at 2.16g/t.
- Total resource estimate: 616kt at 2.28g/t yielding 45koz of gold.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Star Minerals Limited (SMS) ORDINARY FULLY PAID |
Materials |
$10 |
Drilling Highlights Shallow Gold in Western Extension
|
28 Aug 2025 8:29AM |
$0.064 |
$0.039 |
fallen by
39.06%
|
|
SMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Star Minerals Limited announced shallow gold intercepts at Tumblegum South.
- Drilling results include significant gold grades such as 2m at 4.20 g/t Au and 5m at 2.12 g/t Au in hole TGRC068.
- The company completed 38 reverse circulation holes totaling 2,032m.
- Additional drilling is planned to explore further gold mineralization in the western extension.
- Mining approvals are on track for submission in September with production expected in Q1 next year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Doctor Care Anywhere Group PLC (DOC) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$44 |
1H25 Results Announcement
|
28 Aug 2025 8:29AM |
$0.130 |
$0.120 |
fallen by
7.69%
|
|
DOC - Price-sensitive ASX Announcement
Full Release
Key Points
- Gross profit margin of 63.3%, up 8.2 percentage points
- Contribution margin of 50.9%, up 11.4 percentage points
- Underlying EBITDA profit of £2.9 million
- Expansion of clinical model with Mental Health Practitioners and Physiotherapists
- Enhancements to app booking process
- Completion of major transformation program phase
- CEO Laura O’Riordan highlights profitable, cash-generative status
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Doctor Care Anywhere Group PLC (DOC) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$44 |
1H25 Results Announcement
|
28 Aug 2025 8:29AM |
$0.130 |
$0.120 |
fallen by
7.69%
|
|
DOC - Price-sensitive ASX Announcement
Full Release
Key Points
- Gross profit margin of 63.3%, up 8.2ppt
- Contribution margin of 50.9%, up 11.4ppt
- Underlying EBITDA profit of £2.9m
- Expansion with Mental Health Practitioners and Physiotherapists
- Enhanced booking journey on the DCA app
- Major operational streamlining and cost reduction completed
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Doctor Care Anywhere Group PLC (DOC) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$44 |
Interim Financial Report & Appendix 4D
|
28 Aug 2025 8:29AM |
$0.130 |
$0.120 |
fallen by
7.69%
|
|
DOC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for H1 2025 was £19.2 million.
- Gross profit for H1 2025 was £12.2 million.
- Operating profit for H1 2025 was £885,000.
- EBITDA increased to £2.1 million.
- Net profit for H1 2025 was £471,000.
- Revenue decrease was due to Secondary Care Pathway closure.
- BAU revenue increased by 1.6% compared to H1 2024.
- Gross margin improved to 63.3%.
- Cost-saving and restructuring led to financial recovery.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Doctor Care Anywhere Group PLC (DOC) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$44 |
Interim Financial Report & Appendix 4D
|
28 Aug 2025 8:29AM |
$0.130 |
$0.120 |
fallen by
7.69%
|
|
DOC - Price-sensitive ASX Announcement
Full Release
Key Points
- Increased loss after tax due to expanded clinical trials.
- Focus on lead product eftilagimod alfa (efti).
- Significant milestone with TACTI-004 Phase III trial.
- Multiple ongoing trials addressing high unmet needs in oncology.
- Strategic focus on expanding clinical capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Xref Limited (XF1) ORDINARY FULLY PAID |
Information Technology |
$17 |
Xref FY2025 Results Webinar
|
28 Aug 2025 8:28AM |
$0.190 |
$0.078 |
fallen by
58.95%
|
|
| Xref Limited (XF1) ORDINARY FULLY PAID |
Information Technology |
$17 |
Annual Report to shareholders
|
28 Aug 2025 8:28AM |
$0.190 |
$0.078 |
fallen by
58.95%
|
|
Call 1300 880 160
Start a chat
Schedule a call
